Clinical Trial Details

Overview

Research Study Summary

A multicenter, randomized, active-controlled , Phase 3B study to evaluate the Cardiovascular safety of Febuxostat (ULORIC) and Allopurinol in subjects with Gout and Cardiovascular Comorbidities

Purpose

Do you have Gout? You may qualify to participate in a clinical research study.

Cardiovascular Outcomes in gouty arthritis
There are ongoing concerns for the potential of gouty arthritis patients to have a higher risk of adverse cardiovascular events. This trial is seeking gouty arthritis patients with defined cardiovascular events or diabetes who are at high risk for cardiovascular events defined as diabetic patients with microvascular or macrovascular disease. Patients will be randomized to febuxostat (Uloric), in two doses, as well as allopurinol. There will be 5 years of ongoing follow up for enrolled patients.

To Learn more

CW ID: 169940
Date Last Changed: July 23, 2013

Clinical Trial Snapshot

Phase
4
Gender
Both Male and Female
Age
N/A
Overall Status
Recruiting
Duration
5 Years
Facility Type
N/A

Contact

The Center for Rheumatology and Bone Research
2730 University Blvd West, Suite 306
Wheaton, MD 20902
Phone: 301 942-6610
Fax: 301 942-7833

View Map

Research Center Information:

The Center for Rheumatology and Bone Research

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.